07:51 AM EST, 12/12/2024 (MT Newswires) -- Keros Therapeutics ( KROS ) shares were down 72% pre-bell Thursday after the company said it voluntarily halted two treatment arms in a phase 2 study of cibotercept in combination with background therapy in patients with pulmonary arterial hypertension.

Samfine Creation ( SFHG ) stock was 36% lower, extending Wednesday's fall.

Intellinetics ( INLX ) shares were down 21% following a muted session.

Chatham Lodging Trust ( CLDT ) stock was 19% lower after closing nearly unchanged on Wednesday.

Myriad Genetics ( MYGN ) shares were down 17%, adding to Wednesday's losses.